The objective of this project is to devise a novel prodrug strategy for polymeric nanoparticles, seeking a scale-up process for high prodrug loading of a repertoire of poorly water-soluble anticancer drugs, delayed-release, and enhanced delivery into solid tumors.

We hypothesize that delayed release of oligo(lactic acid)n-paclitaxel (PTX) prodrug from poly(ethylene glycol)-block-poly(lactic acid) nanoparticles increases safety and potency of PTX, owing to prolonged tumor exposure, which increases drug action at G2/M phase of the cell cycle.

To enhance antitumor activity against triple-negative breast cancer, we devise co-loaded PTX and signal transduction inhibitor oligo(lactic acid)n-prodrug nanomedicines to prolong, elevate and overlap tumor exposure, aiming for safer and more effective anticancer drug combinations.

Anticancer oligo(lactic acid)n-prodrug nanomedicines for injection

Grant information

  • NIH R01CA257837
    04/01/2021 – 03/31/2025